Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Aagaard Rasmussen

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Advances in Experimental Medicine and Biology|July 22, 2018
Clinical Interventions in HIV Cure ResearchThomas Aagaard Rasmussen, Ole S Søgaard
Trends in Microbiology|December 23, 2015
Reversal of Latency as Part of a Cure for HIV-1Thomas Aagaard Rasmussen, Martin Tolstrup, Ole Schmeltz Søgaard
Expert Review of Anti-Infective Therapy|October 19, 2023
Clinical trials aimed at HIV cure or remission: new pathways and lessons learnedMaya Dyveke Schou, Ole Schmeltz Søgaard, Thomas Aagaard Rasmussen
The Journal of Infectious Diseases|March 26, 2025
Factors influencing virologic control during analytical treatment interruptions in HIV cure trials - a pooled analysis of individual level dataVibeke Klastrup, Jesper Damsgaard Gunst, Thomas Aagaard Rasmussen, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 25, 2018
Patient-reported outcomes in daily clinical practise in HIV outpatient careAnne Sofie Høgh Kølbæk Kjær, Thomas Aagaard Rasmussen, Niels Henrik Hjollund, et al.
AIDS (London, England)|November 24, 2015
HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapySteffen Leth, Rasmus Nymann, Sofie Jørgensen, et al.
Human Vaccines & Immunotherapeutics|February 2, 2013
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activationThomas Aagaard Rasmussen, Ole Schmeltz Søgaard, Christel Brinkmann, et al.
AIDS (London, England)|April 15, 2015
The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patientsAnne Sofie Høgh Kølbæk Kjær, Christel Rothe Brinkmann, Charles A Dinarello, et al.
Msphere|February 23, 2018
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <i>Ex Vivo</i> Lipopolysaccharide-Induced Inflammatory ResponsesChristel Rothe Brinkmann, Jesper Falkesgaard Højen, Thomas Aagaard Rasmussen, et al.
Nature Communications|September 9, 2016
Broad activation of latent HIV-1 in vivoKirston Barton, Bonnie Hiener, Anni Winckelmann, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Advances in Experimental Medicine and Biology|July 22, 2018
Clinical Interventions in HIV Cure ResearchThomas Aagaard Rasmussen, Ole S Søgaard
Trends in Microbiology|December 23, 2015
Reversal of Latency as Part of a Cure for HIV-1Thomas Aagaard Rasmussen, Martin Tolstrup, Ole Schmeltz Søgaard
Expert Review of Anti-Infective Therapy|October 19, 2023
Clinical trials aimed at HIV cure or remission: new pathways and lessons learnedMaya Dyveke Schou, Ole Schmeltz Søgaard, Thomas Aagaard Rasmussen
The Journal of Infectious Diseases|March 26, 2025
Factors influencing virologic control during analytical treatment interruptions in HIV cure trials - a pooled analysis of individual level dataVibeke Klastrup, Jesper Damsgaard Gunst, Thomas Aagaard Rasmussen, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 25, 2018
Patient-reported outcomes in daily clinical practise in HIV outpatient careAnne Sofie Høgh Kølbæk Kjær, Thomas Aagaard Rasmussen, Niels Henrik Hjollund, et al.
AIDS (London, England)|November 24, 2015
HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapySteffen Leth, Rasmus Nymann, Sofie Jørgensen, et al.
Human Vaccines & Immunotherapeutics|February 2, 2013
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activationThomas Aagaard Rasmussen, Ole Schmeltz Søgaard, Christel Brinkmann, et al.
AIDS (London, England)|April 15, 2015
The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patientsAnne Sofie Høgh Kølbæk Kjær, Christel Rothe Brinkmann, Charles A Dinarello, et al.
Msphere|February 23, 2018
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <i>Ex Vivo</i> Lipopolysaccharide-Induced Inflammatory ResponsesChristel Rothe Brinkmann, Jesper Falkesgaard Højen, Thomas Aagaard Rasmussen, et al.
Nature Communications|September 9, 2016
Broad activation of latent HIV-1 in vivoKirston Barton, Bonnie Hiener, Anni Winckelmann, et al.
Pageof 1